Stay updated with breaking news from Operations Financial. Get real-time updates on events, politics, business, and more. Visit us for reliable news and exclusive interviews.
First quarter total revenue of $109 million, Crysvita® revenue of $83 million and Dojolvi® revenue of $16 million Reaffirmed 2024 expected total revenue guidance between $500 million to $530...
Telesis Bio Reports Fourth Quarter and Full Year 2023 Financial Results GlobeNewswire March 28, 2024 SAN DIEGO, March 28, 2024 (GLOBE NEWSWIRE) -- Telesis Bio Inc. (NASDAQ: TBIO), a leading provider of RNA and DNA solutions enabling researchers to accelerate therapeutic discovery through advanced, flexible, and rapid automated synthesis in their own...
2023 Total Revenue of $434 million, Crysvita® revenue of $328 million and Dojolvi® revenue of $71 million 2024 Financial Guidance: Total Revenue between $500 million and $530 million, Crysvita...
13.11.2023 - SAN DIEGO, Nov. 13, 2023 (GLOBE NEWSWIRE) - Telesis Bio Inc. (NASDAQ: TBIO), a leader in automated multi-omic and synthetic biology solutions, today reported financial results for the third quarter of 2023. “This quarter, we continued to drive ...
- Updated luvelta data from Compassionate Use Access demonstrating anti-leukemic activity in pediatric patients with relapsed/refractory CBF2AT3-G...